NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera that is resistant to hydroxycarbamide or for people who cannot tolerate hydroxycarbamide because no evidence submission was received from Novartis Pharmaceuticals for the technology.

  • National Institute for Health and Care Excellence (NICE)